Free Trial
NASDAQ:VTGN

VistaGen Therapeutics (VTGN) Stock Price, News & Analysis

VistaGen Therapeutics logo
$2.92 +0.05 (+1.74%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.90 -0.02 (-0.68%)
As of 08/1/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About VistaGen Therapeutics Stock (NASDAQ:VTGN)

Key Stats

Today's Range
$2.70
$2.94
50-Day Range
$1.96
$3.19
52-Week Range
$1.90
$3.79
Volume
329,032 shs
Average Volume
489,798 shs
Market Capitalization
$87.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

VistaGen Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
21st Percentile Overall Score

VTGN MarketRank™: 

VistaGen Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 842nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for VistaGen Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of VistaGen Therapeutics is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of VistaGen Therapeutics is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    VistaGen Therapeutics has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about VistaGen Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.91% of the float of VistaGen Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VistaGen Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VistaGen Therapeutics has recently decreased by 89.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    VistaGen Therapeutics does not currently pay a dividend.

  • Dividend Growth

    VistaGen Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.91% of the float of VistaGen Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VistaGen Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VistaGen Therapeutics has recently decreased by 89.13%, indicating that investor sentiment is improving significantly.
  • Search Interest

    5 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.29% of the stock of VistaGen Therapeutics is held by insiders.

  • Percentage Held by Institutions

    78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about VistaGen Therapeutics' insider trading history.
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance
See More Headlines

VTGN Stock Analysis - Frequently Asked Questions

VistaGen Therapeutics' stock was trading at $2.95 on January 1st, 2025. Since then, VTGN stock has decreased by 1.0% and is now trading at $2.92.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its earnings results on Tuesday, June, 17th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.09. The business had revenue of ($0.01) million for the quarter, compared to analysts' expectations of $0.18 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative trailing twelve-month return on equity of 58.88%.
Read the conference call transcript
.

VistaGen Therapeutics shares reverse split on the morning of Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

VistaGen Therapeutics' top institutional shareholders include Blair William & Co. IL (0.29%). Insiders that own company stock include Commodore Capital Lp, Shawn Singh, Reid G Adler and Jerry B Gin.
View institutional ownership trends
.

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
6/17/2025
Today
8/02/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTGN
CIK
1411685
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.42 million
Net Margins
-6,777.08%
Pretax Margin
-10,578.40%
Return on Equity
-58.88%
Return on Assets
-52.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.51
Quick Ratio
6.51

Sales & Book Value

Annual Sales
$490 thousand
Price / Sales
177.94
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.44 per share
Price / Book
1.20

Miscellaneous

Outstanding Shares
29,860,000
Free Float
28,782,000
Market Cap
$87.19 million
Optionable
Optionable
Beta
0.40

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:VTGN) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners